Strekin AG, of Basel, Switzerland, presented preclinical data and an update on its phase II development program for STR001 at the Association for Research in Otolaryngology Conference in Baltimore. Read More
Trianni Inc., of San Francisco, agreed to license the use of its Trianni Mouse, a monoclonal antibody discovery platform, to Janssen Biotech Inc., a unit of Johnson & Johnson, of New Brunswick, N.J. The platform provides access to a complete human antibody repertoire optimized for the rapid isolation of fully human therapeutics. Read More
Auris Medical Holding AG, of Zug, Switzerland, priced a public offering of 10 million common shares and 10 million warrants that each entitle its holder to purchase 0.70 of a common share. Read More
Alkermes plc, of Dublin, reported that for the year ending Dec. 31, 2016, total revenues increased 19 percent, to $745.7 million, which included net sales of $209.0 million for Vivitrol (naltrexone for extended-release injectable suspension) and net sales of $47.2 million for the schizophrenia drug, Aristada (aripiprazole lauroxil). Read More
DUBLIN – Jecure Therapeutics Inc. raised $20 million in series A funding for the discovery and development of therapeutics to treat non-alcoholic steatohepatitis (NASH) and liver fibrosis, based on new insights into the sterile inflammatory processes that drive the disease. Read More
Key opinion leaders (KOLs) were "giddy" about Ardelyx Inc.'s phase III data with tenapanor for hyperphosphatemia in patients with end-stage renal disease who are on dialysis, said CEO Mike Raab, and the company is putting together plans for another experiment that could lead to approval. Read More
DUBLIN – Inventiva SA raised €48 million ($50.9 million) in the third European biotech IPO of 2017. The Dijon, France-based drug developer priced the offer at €8.50 per share, at the bottom of the indicative range of €8.50 to €9.75 it set at the start of the bookbuilding process. Read More
A nonvirulent tumor-targeting bacterial strain bioengineered to release multiple Toll-like receptor (TLR) ligands was shown to suppress tumor growth and prolong survival in mouse tumor models in a Korean study, suggesting it could be a new cancer immunotherapy in humans. Read More
Merck & Co. Inc. is calling a halt to a high-profile phase II/III study of verubecestat after data monitors found "virtually no chance of finding a positive clinical effect" for patients with mild to moderate Alzheimer's disease. Read More
